Division of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital, Zhengzhou University , Zhengzhou , China and.
Clin Exp Hypertens. 2015;37(1):51-6. doi: 10.3109/10641963.2014.897722. Epub 2014 Mar 28.
We investigated blood nesfatin-1 levels in hypertension patients. We found that fasting plasma nesfatin-1 levels were significantly higher in hypertension patients than in control groups, especially in overweight/obese hypertension patients (4.5 ± 2.1 versus 3.3 ± 1.1 ng/ml, p < 0.01). Body mass index, systolic blood pressure and diastolic blood pressure were indeed positively correlated with fasting plasma nesfatin-1 levels (r = 0.234, p < 0.05; r = 0.304, p < 0.01; r = 0.251, p < 0.05; r = 0.461, p < 0.01; respectively). Logistic regression analysis revealed that the plasma level of nesfatin-1 could be independent of risk prediction over standard measures (OR = 1.547, 95% CI: 1.153-6.273, p = 0.026). Nesfatin-1 has the incremental contribution to hypertension risk prediction (IDI: 0.014, p = 0.018; NRI: 0.050, p = 0.043). The plasma nesfatin-1 level in hypertension patients with microalbuminuria are significantly higher than those without microalbuminuria patients (6.4 ± 2.1 ng/ml versus 3.9 ± 1.8 ng/ml, p < 0.01). Nesfatin-1 might play an important role in obesity hypertension, and its increase could be a risk factor for obesity-associated hypertension.
我们研究了高血压患者的血液 nesfatin-1 水平。我们发现，与对照组相比，高血压患者的空腹血浆 nesfatin-1 水平明显更高，尤其是超重/肥胖的高血压患者（4.5±2.1 与 3.3±1.1ng/ml，p<0.01）。体重指数、收缩压和舒张压与空腹血浆 nesfatin-1 水平呈正相关（r=0.234，p<0.05；r=0.304，p<0.01；r=0.251，p<0.05；r=0.461，p<0.01；分别）。Logistic 回归分析显示，血浆 nesfatin-1 水平可独立于标准指标进行风险预测（OR=1.547，95%CI：1.153-6.273，p=0.026）。nesfatin-1 对高血压风险预测有额外的贡献（IDI：0.014，p=0.018；NRI：0.050，p=0.043）。微量白蛋白尿的高血压患者的血浆 nesfatin-1 水平明显高于无微量白蛋白尿的患者（6.4±2.1ng/ml 与 3.9±1.8ng/ml，p<0.01）。nesfatin-1 可能在肥胖性高血压中起重要作用，其增加可能是肥胖相关高血压的危险因素。
